SynthesisHormones (Athens, Greece)2025
Cisapride for gastric emptying in diabetic patients: a meta-analysis on its efficacy and safety.
Synthesis in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic gastroparesis is a common complication of diabetes, characterized by delayed gastric emptying, significantly impacting patients' quality of life. Current treatment options are limited often resulting in unsatisfactory outcomes. This meta-analysis aims to evaluate the efficacy and safety of cisapride in diabetic patients suffering from gastroparesis.
methodsA systematic literature search identified 13 studies involving 185 participants. Data on gastric emptying rates, symptom relief, and safety profiles were extracted and analyzed. Effectiveness was measured through gastric emptying half-life (T1/2, measured in min), 120-min gastric emptying rate (measured as a percentage), and adverse events. KEY
resultsThe analysis revealed that cisapride significantly improved gastric emptying compared to placebo, with a mean difference (MD) of -33.74 for T1/2 (95% CI: -68.84 to -2.65, P = 0.03). Additionally, the 120-min gastric emptying rate improved by -25.84 (95% CI: -16.80 to -25.84, P < 0.001). The occurrence of adverse events was low, with most patients tolerating the treatment well. CONCLUSION AND INFERENCES: Cisapride demonstrates notable efficacy in improving gastric emptying in diabetic gastroparesis, with a generally acceptable safety profile. Clinicians should consider cisapride as a viable treatment option while monitoring patients for any potential side effects. Further research is warranted to explore long-term safety and effectiveness.
Indexed as
Identifiers
40569325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.